This article is more than 5 years old. Information may no longer be current.
IND submitted to study mazindol for ADHD in adults
Click Here to Manage Email Alerts
The NLS Pharma Group recently announced submission of an Investigational New Drug Application to the FDA to study mazindol for attention-deficit/hyperactivity disorder in adults.
Pending acceptance, Tim L. Wigal, PhD, of the University of California Irvine, and colleagues will conduct a phase IIb clinical trial to determine the efficacy, safety, tolerability and pharmacokinetics of controlled-release mazindol in adults with ADHD.
Approximately 6.4 million individuals aged younger than 18 years have been diagnosed with ADHD and research shows that more than 10 million adults have ADHD in the United States.
“With the submission of this IND, NLS Pharma has achieved an additional major milestone in its development program of NLS1001 for ADHD,” Alex Zwyer, MBA, CEO of NLS Pharma, said in a press release.